Sj ögren Syndrome and Cancer.
This article discusses the accumulating data on various malignancies described in primary Sjögren syndrome, highlighting non-Hodgkin lymphoma and thyroid, multiple myeloma, and skin cancers. These reported associations may have clinical implications in daily practice and contribute to understanding of both autoimmunity and cancer. PMID: 32631601 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 9, 2020 Category: Cancer & Oncology Authors: Igoe A, Merjanah S, Scofield RH Tags: Rheum Dis Clin North Am Source Type: research

Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Abstract Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Although median overall survival rates exceed 12 years with rituximab, follicular lymphoma remains largely incurable. The growing understanding of the molecular drivers of lymphomagenesis and the tumor microenvironment have led to novel therapies. Prognostic markers have identified a subset of patients with chemoresistant and/or refractory disease-associated poor outcomes. We identify the patients with follicular lymphoma in need of novel therapies, describe the drivers of lymphomagenesis and importance of the tumor microenvironmen...
Source: Clinical Lymphoma and Myeloma - June 27, 2020 Category: Cancer & Oncology Authors: Chin CK, Nastoupil LJ Tags: Hematol Oncol Clin North Am Source Type: research

Retraction Notice.
Authors: PMID: 32553269 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 20, 2020 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: A case study.
CONCLUSIONS: Bone marrow particle enrichment analysis may be applied to overcome the problems caused by hemodilution of bone marrow aspirates and to improve the rate of tumor cell detection. The application of this method for the diagnosis of hematological disorders should be explored further. PMID: 32548852 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 16, 2020 Category: Cancer & Oncology Authors: Zhang C, Zhang Y Tags: J Clin Lab Anal Source Type: research

Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
CONCLUSION: This modified pre-lysis procedure provides a sensitive, robust, time efficient, and relatively cost-effective alternative for MRD testing by MFC at 10-5 , facilitating clinically meaningful deeper response assessment for MM, CLL, and B-NHL. This method adaptation may facilitate more widespread adoption of highly sensitive flow cytometry-based MRD assessment. PMID: 32530574 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 12, 2020 Category: Cancer & Oncology Authors: Bayly E, Nguyen V, Binek A, Piggin A, Baldwin K, Westerman D, Came N Tags: Cytometry B Clin Cytom Source Type: research

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
CONCLUSIONS: Our study provides a proof-of-concept that warrants the clinical evaluation of DCZ3301 as a novel anti-tumor compound against BTZ resistance in MM. PMID: 32517809 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 9, 2020 Category: Cancer & Oncology Authors: Hu L, Li B, Chen G, Song D, Xu Z, Gao L, Xi M, Zhou J, Li L, Zhang H, Feng Q, Wang Y, Lu K, Lu Y, Bu W, Wang H, Wu X, Zhu W, Shi J Tags: J Exp Clin Cancer Res Source Type: research

Chimeric Antigen Receptor T-cell Therapy Toxicities.
Abstract Cancer immunotherapy has greatly advanced in recent years, with chimeric antigen receptor (CAR) T-cells emerging as an innovative technology that harnesses the immune system to fight malignant diseases. These genetically engineered T-cells have shown encouraging results for B-cell lymphoid malignancies and are now being explored for other cancer types. However, this novel adoptive cell therapy is associated with a new spectrum of immune-mediated adverse events and toxicities. As CAR-T cells recognize and engage tumor cells, cytokines are secreted and activate other immune cells, frequently leading to rapi...
Source: Clinical Lymphoma and Myeloma - May 28, 2020 Category: Cancer & Oncology Authors: Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ Tags: Br J Clin Pharmacol Source Type: research

Prognostic Value of Baseline Serum Lactate Dehydrogenase Level in Patients With Hairy Cell Leukemia.
Abstract BACKGROUND: Hairy cell leukemia is a rare B-cell lymphoproliferative disorder. It has an indolent course with relapse and remission periods. The aim of this study was to investigate the clinical characteristics and risk factors affecting the outcome of patients with hairy cell leukemia. PATIENTS AND METHODS: The retrospective data of 65 patients were evaluated according to initial hematologic and biochemical parameters, response rates, progression-free survival, and overall survival. Factors effecting response and survival rates were analyzed. RESULTS: The median follow-up duration was 62.8 mont...
Source: Clinical Lymphoma and Myeloma - April 22, 2020 Category: Cancer & Oncology Authors: Maral S, Albayrak M, Dagdas S, Yıldız A, Yıldırım R, Oz M, Pala C, Afacan Ozturk HB, Bay I, Ozet G, Dilek I Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma.
Abstract BACKGROUND: Multiple studies have demonstrated the efficacy and safety of daratumumab for relapsed/refractory multiple myeloma (MM) and primary treatment for transplant-eligible and -ineligible patients. MATERIALS AND METHODS: We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with daratumumab versus comparators. Data were pooled from 5 completed phase III randomized controlled studies that had included 1798 daratumumab-treated and 1797 comparator-treated patients with MM as a first line in both transplant-eligible...
Source: Clinical Lymphoma and Myeloma - April 20, 2020 Category: Cancer & Oncology Authors: Al Hadidi S, Miller-Chism CN, Kamble R, Mims M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting.
Abstract In this review, we summarize novel clinical data on multiple myeloma (MM) that were presented at the 2019 annual meeting of the American Society of Hematology. The Master trial showed that a response-adapted approach may effectively guide therapeutic decisions in terms of treatment intensification after autologous transplantation among patients with newly diagnosed MM. The Alcyone study confirmed the superiority of adding daratumumab to the backbone combination of bortezomib, melphalan, and dexamethasone among diagnosed MM patients unfit for transplantation, which resulted in a significant overall surviva...
Source: Clinical Lymphoma and Myeloma - April 15, 2020 Category: Cancer & Oncology Authors: Terpos E, Ntanasis-Stathopoulos I, International Myeloma Society Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Abstract INTRODUCTION: We conducted a retrospective multicenter cohort study of patients receiving Immunoglobulin replacement therapy (IgRT) for secondary immune deficiency (SID) during 2012. METHODS: Data were retrospectively collected from the first dose of Ig administered in 2012 to 1 year afterward in terms of the indication for IgRT, as well as efficacy and safety. RESULTS: In total, 16 hospitals participated in the study, and 368 patients were included. Indications for IgRT were non-Hodgkin lymphoma (82 [22.3%] patients), multiple myeloma (76 [20.7%]), chronic lymphocytic leukemia (64 [17.4%]) an...
Source: Clinical Lymphoma and Myeloma - April 11, 2020 Category: Cancer & Oncology Authors: Legendre P, Chahwan D, Marjanovic Z, Vignon M, Hermine O, Lortholary O, Morelle G, Darrodes M, Kahn JE, Ouzegdouh M, Chaibi P, Montestruc F, Caumont-Prim A, Le Jouan M, Hassani Y, Godeau B, Durand-Zaleski I, Mouthon L Tags: Clin Immunol Source Type: research

The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement.
PMID: 32278675 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 16, 2020 Category: Cancer & Oncology Authors: Fay E, Herzig D, Sharzehi K, Spurgeon SE Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade.
PMID: 32179034 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 13, 2020 Category: Cancer & Oncology Authors: Peringeth G, Torka P, Wong J, Hernandez-Ilizaliturri FJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Aggressive Tongue Root Epstein-Barr Virus-Positive Mucocutaneous Ulcer Treated With Rituximab Alone.
PMID: 32179033 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 3, 2020 Category: Cancer & Oncology Authors: Tsutsumi M, Yoshimura T, Tatsumi N, Nakaya Y, Fuseya H, Horiuchi M, Yoshida M, Hayashi Y, Nakao T, Inoue T, Yamane T Tags: Clin Lymphoma Myeloma Leuk Source Type: research

High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Abstract Multiple myeloma, a bone marrow cancer, is preceded by precursor stages called monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Over the past few years, highly effective and safe therapies have been made available to treat multiple myeloma. This represents a major breakthrough and has major therapeutic implications. Treatment for multiple myeloma has evolved to include treatment of precursor stages (early treatment) as these therapies are shown to be safe and effective also in smoldering myeloma. Randomized studies have shown that early treatment can delay the onset of multip...
Source: Clinical Lymphoma and Myeloma - March 1, 2020 Category: Cancer & Oncology Authors: Kunacheewa C, Manasanch EE Tags: Best Pract Res Clin Haematol Source Type: research

Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study.
CONCLUSIONS: Broad-spectrum antibiotics were common in patients with haematological malignancies in Japan; however, antibiotic-resistant bacteria including carbapenem-resistant or multidrug-resistant bacteria were infrequent. Our results provide nationwide, cross-sectional insight into the use of antimicrobial agents, prevalence of bacteria, and antibiotic resistance, demonstrating differences in antimicrobial utilization among different haematological diseases. PMID: 32066448 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 17, 2020 Category: Cancer & Oncology Authors: Mimura W, Fukuda H, Akazawa M Tags: Ann Clin Microbiol Antimicrob Source Type: research

Corrigendum.
Authors: PMID: 32067955 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 14, 2020 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Hematologic Malignancies.
Abstract Radiation therapy plays a critical role in the management of a wide range of hematologic malignancies. The optimal radiation dose and target volume, and safe and effective ways of integrating radiation with systemic agents, vary depending on the histologic subtypes, stage at presentation, patient performance status, response to systemic therapy if given, treatment intent, and patient preferences. Limiting doses to surrounding organs without sacrificing disease control is of paramount importance. Reducing radiation doses and treatment volume in selected cases, and the use of advanced radiotherapy technolog...
Source: Clinical Lymphoma and Myeloma - November 21, 2019 Category: Cancer & Oncology Authors: Tseng YD, Ng AK Tags: Hematol Oncol Clin North Am Source Type: research

False-Positive Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy.
We describe three clinical scenarios in which CAR T- cell immunotherapy interfered with HIV-1 testing including: (1) routine infectious disease screening prior to stem cell transplantation in a 16-year-old female with B-cell acute lymphoblastic leukemia, status post CAR T- cell treatment (2) routine infectious disease screening prior to 2nd CAR T- cell collection in a 65-year-old male with diffuse large B-cell lymphoma who failed initial CAR T- cell treatment and (3) routine infectious risk assessment following an occupational health exposure from a 58 -year-old male with multiple myeloma, status post CAR T- cell treatment...
Source: Clinical Lymphoma and Myeloma - November 6, 2019 Category: Cancer & Oncology Authors: Hauser JR, Hong H, Babady NE, Papanicolaou GA, Tang YW Tags: J Clin Microbiol Source Type: research

The comparison of effectiveness and safety between different biosimilars of G-CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto-PBSCT).
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 30, 2019 Category: Cancer & Oncology Authors: Wicherska-Pawłowska K, Rybka J, Prajs I, Szmigiel K, Tyc J, Frączak E, Biedroń M, Kalicińska E, Szymczak D, Wróbel T Tags: J Clin Apher Source Type: research

CAR T-cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Abstract The development of chimeric antigen receptor (CAR) T-cell therapy for select hematological malignancies represents one of the most remarkable therapeutic advances in the past decade. Currently, CD19-targeted CAR T-cell therapy is approved for relapsed/refractory diffuse large B cell lymphoma and acute lymphoblastic leukemia. However, there is significant interest in the application of CAR T-cell therapy to other hematological malignancies, including multiple myeloma, where the current focus is on the development of B cell maturation antigen-directed CAR T-cell therapy. Despite the successes achieved to da...
Source: Clinical Lymphoma and Myeloma - October 17, 2019 Category: Cancer & Oncology Authors: Holstein SA, Lunning MA Tags: Clin Pharmacol Ther Source Type: research

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D Abstract PURPOSE: MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of MYC-R (single-, double-, and triple-hit statu...
Source: Clinical Lymphoma and Myeloma - September 9, 2019 Category: Cancer & Oncology Authors: Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Tags: J Clin Oncol Source Type: research

Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.
CONCLUSION: CART-related GI-AEs occur in 15% of patients treated with CART. These symptoms are typically mild and self-limiting, requiring only symptomatic treatment. Nevertheless, CART may, in rare cases, lead to refractory colitis. PMID: 31478934 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 30, 2019 Category: Cancer & Oncology Authors: Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y Tags: Am J Clin Oncol Source Type: research

SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Abstract Therapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immunotherapies approved for multiple myeloma, a cancer of plasma cells. These agents are effective, particularly in combination with the immunomodulatory drugs lenalidomide and pomalidomide. The next generation of myeloma immunotherapy under investigation consists of T-cell-directed strategies designed to promote cytotoxic activity against myeloma cells, as embodied by chimeric antigen receptor-modified T cells (CAR-T) and bispecific T-cell-engaging agents. Early clinical trial results with these classes of ther...
Source: Clinical Lymphoma and Myeloma - August 7, 2019 Category: Cancer & Oncology Authors: Madduri D, Dhodapkar MV, Lonial S, Jagannath S, Cho HJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation.
Abstract BACKGROUND: Obesity has implications for hematopoietic progenitor cell (HPC) mobilization, chemotherapy administration, and medication dosing. We analyzed the impact of obesity on HPC mobilization as well as key outcomes that are associated with cell dose in autologous hematopoietic cell transplantation (AHCT) recipients. METHODS: We conducted a retrospective cohort study on 556 consecutive eligible AHCT recipients at our institution from 1/2004 to 12/2009. Patients were categorized into four groups based on the body mass index (BMI): underweight (BMI 
Source: Clinical Lymphoma and Myeloma - August 5, 2019 Category: Cancer & Oncology Authors: Khouri J, Rybicki L, Majhail NS, Kalaycio M, Pohlman B, Hill B, Jagadeesh D, Dean R, Hamilton B, Sobecks R, Koo A, Liu H Tags: J Clin Apher Source Type: research

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population. METHODS: A total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis. RESULTS: The pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance ov...
Source: Clinical Lymphoma and Myeloma - July 22, 2019 Category: Cancer & Oncology Authors: Ogasawara K, Newhall K, Maxwell SE, Dell'Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y Tags: Clin Pharmacokinet Source Type: research

Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Abstract The treatment of adult acute lymphoblastic leukemia (ALL) has largely followed the successful pediatric model that uses multi-agent chemotherapy regimens. Although cytotoxic chemotherapy can induce complete remissions, elderly patients are frequently unable to tolerate its intensity owing to toxicities and comorbidities. Elderly patients particularly often relapse, leading to a 5-year overall survival (OS) of only 20%. In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; c...
Source: Clinical Lymphoma and Myeloma - July 3, 2019 Category: Cancer & Oncology Authors: Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies.
This article discusses recent advances in PET quantification that can improve reliability and accuracy of characterizing hematological malignancies." PMID: 31084773 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 16, 2019 Category: Cancer & Oncology Authors: Raynor WY, Zadeh MZ, Kothekar E, Yellanki DP, Alavi A Tags: PET Clin Source Type: research

68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma.
We report a case of plasmacytoma with suspicious renal cell carcinoma, in whom Ga CXCR-4 PET/CT revealed tracer-avid lesion in the left perinephric region. PET/CT-guided biopsy from the tracer-avid lesion revealed plasmacytoma. PET/CT-imaging and guided biopsy using Ga CXCR4 receptor ligand, proved its usefulness for accurate localization of the culprit lesion and helped in definitive management of the patient. PMID: 30985424 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 12, 2019 Category: Cancer & Oncology Authors: Kumar R, Mittal BR, Sood A, Singh H, Shukla J, Nada R, Rathi M Tags: Clin Nucl Med Source Type: research

Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Abstract Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in the allogenic stem cell transplant (allo-SCT) setting. It is possible that the efficacy of mogamulizumab could be established by the occurrence of skin rashe...
Source: Clinical Lymphoma and Myeloma - March 23, 2019 Category: Cancer & Oncology Authors: Ureshino H, Kamachi K, Kimura S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.
Abstract BACKGROUND: With the improvement in the survival of breast cancer, developing second primary malignancy becomes a serious health issue. The aim of this study was to explore the survival of breast cancer patients with second primary malignancy, and to evaluate the impact of chemotherapy on the risk of different cancer sites. METHOD: Obtaining data from the Surveillance, Epidemiology, and End Results database, we calculated the standardized incidence ratio (SIR) for second primary malignancy in breast cancer survivors between 2000 and 2014. Overall survival and cancer-specific survival were analyzed wi...
Source: Clinical Lymphoma and Myeloma - March 19, 2019 Category: Cancer & Oncology Authors: Wei JL, Jiang YZ, Shao ZM Tags: Int J Clin Oncol Source Type: research

Waldenstr öm Macroglobulinemia: Unusual Presentation With Cast Nephropathy/Light Chain Tubulopathy.
We present an interesting case of Cast Nephropathy and light chain tubulopathy in an 81-year-old female patient with Waldenstrom Macroglobulinemia who required medical attention for worsening renal failure. Serum protein electrophoresis/Immunofixation showed IgM Kappa monoclonal gammopathy. Renal biopsy was remarkable for cast nephropathy and light chain tubulopathy. Furthermore on bone marrow biopsy a low grade B cell lymphoproliferative disorder with plasmacytic differentiation was present. This was most consistent with lymphoplasmacytic lymphoma, accounting for 50-60 percent of total bone marrow cellularity, in a hyperc...
Source: Clinical Lymphoma and Myeloma - February 27, 2019 Category: Cancer & Oncology Authors: Ashraf M, Rastogi P Tags: Clin Med Insights Case Rep Source Type: research

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
CONCLUSION: The Sebia FLC assay provides inequivalent absolute results from the Freelite assay. Despite lower absolute FLC values, the kinetics of response and relapse is exactly the same. As with other FLC assays available, follow-up of MM with the same method is advisable. PMID: 30799237 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2019 Category: Cancer & Oncology Authors: Caillon H, Avet-Loiseau H, Attal M, Moreau P, Decaux O, Dejoie T Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
This study aimed to develop a population pharmacokinetic model for lenalidomide in multiple cancers, including CLL, to identify any disease-related differences in disposition. METHODS: Lenalidomide concentrations from four clinical trials were collated (1999 samples, 125 subjects), covering four cancers (multiple myeloma, CLL, acute myeloid leukaemia and acute lymphoblastic leukaemia) and a large dose range (2.5 - 75mg). A population pharmacokinetic model was developed with NONMEM, and patient demographics were tested as covariates. RESULTS: The data were best fitted by a one-compartment kinetic model with absorp...
Source: Clinical Lymphoma and Myeloma - January 22, 2019 Category: Cancer & Oncology Authors: Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR Tags: Br J Clin Pharmacol Source Type: research

Acalabrutinib for adults with mantle cell lymphoma.
Abstract INTRODUCTION: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains the great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. However, ibrutinib-related adverse events due to off-target inhibition of other kinases, led to the development of more selective molecules with comparable efficacy and ...
Source: Clinical Lymphoma and Myeloma - January 14, 2019 Category: Cancer & Oncology Authors: Jurczak W, Długosz-Danecka M, Wang M Tags: Expert Rev Clin Pharmacol Source Type: research

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
CONCLUSION: Binimetinib had tolerable safety profile with a minimal response in RAS-mutant AML. Future studies should focus on better patient selection and synergistic combination therapies involving MEK inhibition. PMID: 30635233 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 20, 2018 Category: Cancer & Oncology Authors: Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
Abstract BACKGROUND: Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML. PATIENTS AND METHODS: We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AM...
Source: Clinical Lymphoma and Myeloma - December 6, 2018 Category: Cancer & Oncology Authors: Ciftciler R, Demiroglu H, Buyukasık Y, Aladag E, Aksu S, Haznedaroglu IC, Sayınalp N, Ozcebe O, Malkan UY, Goker H Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
PMID: 30594446 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Bond DA, Dotson E, Awan FT, Baiocchi RA, Blum KA, Maddocks K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Chronic Neutrophilic Leukemia: Current and Future Perspectives.
Abstract Chronic neutrophilic leukemia (CNL) is a BCR-ABL1-negative myeloproliferative neoplasm with notably dismal survival. The current 2016 World Health Organization classification of myeloid neoplasms enables clinicians to unequivocally differentiate CNL from its comparable myelodysplastic/myeloproliferative neoplasm overlap syndromes. Additionally, the gradual emergence of next-generation sequencing has progressively expanded our evolving understanding of the molecular pathogenesis of CNL and its therapeutic potential. Hematopoietic stem-cell transplantation remains the primary therapeutic option for the effe...
Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Venugopal S, Mascarenhas J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
CONCLUSION: There are a number of challenges associated with the use of copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, although they are transient, reversible, and rarely of clinical significance; this report provides guidance as to their management. PMID: 30584024 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
CONCLUSIONS: The five serum markers, LDH, IgM, IgG, IgA, and К, each yielded a specific efficacy in differential diagnosis of WM. The single marker with the highest diagnostic efficiency was the serum IgM level. However, a combination of multiple serum markers was better than the use of a single marker in diagnosing WM. The combined use of all five serum markers provided the most effective diagnosis, with an AUC of .952 and sensitivity and specificity of 87.8% and 86.9%, respectively. PMID: 30485557 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 28, 2018 Category: Cancer & Oncology Authors: Zou H, Yang R, Liao ZX, Qin TD, Chen P, Zhang BY, Cao YP, Huang HF Tags: J Clin Lab Anal Source Type: research

Systemic Capillary Leak Syndrome (Clarkson Syndrome) in Cancer Patients: A Systematic Review.
Abstract Systemic capillary leak syndrome (SCLS) is a rare disease characterized by shock caused by capillary hyperpermeability. The disease can occur in cancer patients and effective therapeutic strategies have not been established yet. The aim of the study was to analyze the clinical and laboratory data, treatment modalities, and mortality rate of patients and to identify contributing factors leading to mortality of SCLS in cancer. We searched MEDLINE (inception to July 2018) and of 4612 articles, we identified 62 case reports on SCLS associated with cancer or cancer-related drugs in a total of 53 articles. SCLS...
Source: Clinical Lymphoma and Myeloma - November 6, 2018 Category: Cancer & Oncology Authors: Shin JI, Lee KH, Lee IR, Oh JH, Kim DW, Shin JW, Eo TS, Kronbichler A, Eisenhut M, van der Vliet HJ Tags: J Clin Med Source Type: research

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.
We present a review of the current literature regarding HS diagnosis, treatment, and outcomes. Additionally, we describe the first reported case of HS transdifferentiated from follicular lymphoma that had a dramatic and durable response to rituximab/bendamustine alone as initial treatment. Unlike traditional chemotherapy regimens, this treatment was well tolerated and had a good toxicity profile. The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are be...
Source: Clinical Lymphoma and Myeloma - October 13, 2018 Category: Cancer & Oncology Authors: Farris M, Hughes RT, Lamar Z, Soike MH, Menke JR, Ohgami RS, Winkfield K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
PMID: 30392824 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 13, 2018 Category: Cancer & Oncology Authors: Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk NWCJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Corrigendum.
Authors: PMID: 30249331 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 26, 2018 Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Whole-Body MR Imaging: The Novel, "Intrinsically Hybrid," Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond.
Whole-Body MR Imaging: The Novel, "Intrinsically Hybrid," Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond. PET Clin. 2018 Oct;13(4):505-522 Authors: Lecouvet FE, Van Nieuwenhove S, Jamar F, Lhommel R, Guermazi A, Pasoglou VP Abstract Whole-body MR imaging (WB-MR imaging) has become a modality of choice for detecting bone metastases in multiple cancers, and bone marrow involvement by multiple myeloma or lymphoma. Combination of anatomic and functional sequences imparts an inherently hybrid dimension to this nonirradiating tool and extends the screening of malignancies outside t...
Source: Clinical Lymphoma and Myeloma - September 18, 2018 Category: Cancer & Oncology Authors: Lecouvet FE, Van Nieuwenhove S, Jamar F, Lhommel R, Guermazi A, Pasoglou VP Tags: PET Clin Source Type: research

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization.
Conclusions: Late afternoon administration of plerixafor provides efficient stem cell mobilization. PMID: 30186032 [PubMed] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 8, 2018 Category: Cancer & Oncology Authors: El Rahi C, Cox JE, May R, Carrum G, Anyadike GO, Scholoff A, Kamble R Tags: Clin Med Insights Blood Disord Source Type: research

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
CONCLUSION: The combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL. PMID: 30122201 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 22, 2018 Category: Cancer & Oncology Authors: Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
CONCLUSION: These data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients. PMID: 30122202 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 22, 2018 Category: Cancer & Oncology Authors: Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
This study aimed to evaluate correlates of TKI NA using EM and test the diagnostic accuracy of subjective adherence measures. PATIENTS AND METHODS: CML patients receiving a TKI for any duration were enrolled at 4 hematology institutes, and adherence was measured for 4 months. EM adherence was the reference adherence measure, expressed as the percentage of days with the drug taken as prescribed. Subjective adherence was measured using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) self-report and clinician-reported visual analog scale (VAS) at 2 time points. Baseline theory-derived co...
Source: Clinical Lymphoma and Myeloma - August 22, 2018 Category: Cancer & Oncology Authors: Leader A, Gafter-Gvili A, Benyamini N, Dreyer J, Calvarysky B, Amitai A, Yarchovsky-Dolberg O, Sharf G, Tousset E, Caspi O, Ellis M, Levi I, Raanani P, De Geest S Tags: Clin Lymphoma Myeloma Leuk Source Type: research